Predictive Oncology Inc
POAI5.950USD
0.000
收盘 12/24, 13:00（美东）报价延迟15分钟
4.56M总市值
亏损市盈率 TTM
关于 Predictive Oncology Inc 公司
Predictive Oncology Inc. is engaged in using artificial intelligence (AI) and machine learning to expedite early drug discovery and enable drug development for the benefit of cancer patients worldwide. The Company’s scientifically validated AI platform, PEDAL, is able to predict with 92% accuracy when a tumor sample responds to a certain drug compound, allowing for a more informed selection of drug/tumor type combinations for subsequent in-vitro testing. Through AI, it uses its proprietary biobank of 150,000+ cancer tumor samples, categorized by patient type, against drug compounds to help the drug discovery process and increase the probability of drug development. The Company offers a suite of solutions for oncology drug development from early discovery to clinical trials.
Predictive Oncology Inc简介
公司代码POAI
公司名称Predictive Oncology Inc
上市日期Dec 18, 2009
CEOVennare (Raymond F)
员工数量23
证券类型Ordinary Share
年结日Dec 18
公司地址91 43Rd Street
城市PITTSBURGH
上市交易所NASDAQ OMX - NASDAQ BASIC
国家United States of America
邮编15201
电话14124321500
网址https://predictive-oncology.com/
公司代码POAI
上市日期Dec 18, 2009
CEOVennare (Raymond F)
Predictive Oncology Inc公司高管
名称
名称/职务
职务
持股
持股变动
Mr. Joshua Blacher
Mr. Joshua Blacher
Interim Chief Financial Officer
Interim Chief Financial Officer
6.47K
--
Mr. Raymond F. Vennare
Mr. Raymond F. Vennare
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
6.43K
-26.95%
Dr. Daniel E. (Dan) Handley, Ph.D.
Dr. Daniel E. (Dan) Handley, Ph.D.
Independent Director
Independent Director
5.45K
--
Dr. Veena Rao, Ph.D.
Dr. Veena Rao, Ph.D.
Independent Director
Independent Director
4.92K
--
Mr. Thomas McLaughlin
Mr. Thomas McLaughlin
Chief Investment Officer
Chief Investment Officer
--
--
Ms. Sara Turken
Ms. Sara Turken
General Counsel
General Counsel
--
--
Mr. Shawn P. Matthews
Mr. Shawn P. Matthews
Director
Director
--
--
Dr. Matthew J. Hawryluk, Ph.D.
Dr. Matthew J. Hawryluk, Ph.D.
Independent Director
Independent Director
--
--
Mr. Gregory S. St. Clair, Sr.
Mr. Gregory S. St. Clair, Sr.
Independent Director
Independent Director
--
--
Mr. Chuck (Charles) Nuzum, Sr.
Mr. Chuck (Charles) Nuzum, Sr.
Lead Independent Director
Lead Independent Director
--
--
名称
名称/职务
职务
持股
持股变动
Mr. Joshua Blacher
Mr. Joshua Blacher
Interim Chief Financial Officer
Interim Chief Financial Officer
6.47K
--
Mr. Raymond F. Vennare
Mr. Raymond F. Vennare
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
6.43K
-26.95%
Dr. Daniel E. (Dan) Handley, Ph.D.
Dr. Daniel E. (Dan) Handley, Ph.D.
Independent Director
Independent Director
5.45K
--
Dr. Veena Rao, Ph.D.
Dr. Veena Rao, Ph.D.
Independent Director
Independent Director
4.92K
--
Mr. Thomas McLaughlin
Mr. Thomas McLaughlin
Chief Investment Officer
Chief Investment Officer
--
--
Ms. Sara Turken
Ms. Sara Turken
General Counsel
General Counsel
--
--
收入明细
由于公司未披露，未能获取相关数据
由于公司未披露，未能获取相关数据
业务
地区
由于公司未披露，未能获取相关数据
股东统计
更新时间: 11月16日 周日
更新时间: 11月16日 周日
持股股东
股东类型
持股股东
持股股东
占比
Luo (Weiyu)
2.89%
SLN Capital Ltd
1.73%
Diametric Capital
0.15%
Blacher (Joshua)
0.04%
Vennare (Raymond F)
0.04%
其他
95.15%
持股股东
持股股东
占比
Luo (Weiyu)
2.89%
SLN Capital Ltd
1.73%
Diametric Capital
0.15%
Blacher (Joshua)
0.04%
Vennare (Raymond F)
0.04%
其他
95.15%
股东类型
持股股东
占比
Individual Investor
3.19%
Corporation
1.73%
Investment Advisor/Hedge Fund
0.15%
其他
94.93%
机构持股
更新时间: 10月1日 周三
更新时间: 10月1日 周三
报告期
机构数
持股数
持股占比
持股变动
2025Q3
37
7.39K
0.21%
-26.00K
2025Q2
44
299.51K
2.93%
-288.64K
2025Q1
50
299.35K
3.35%
-293.31K
2024Q4
56
353.94K
4.97%
-213.96K
2024Q3
54
322.08K
5.97%
-246.26K
2024Q2
57
408.73K
8.00%
-114.07K
2024Q1
66
484.20K
11.91%
-86.59K
2023Q4
66
502.45K
12.36%
-67.11K
2023Q3
69
499.46K
12.41%
-50.95K
2023Q2
67
353.15K
8.84%
-144.84K
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Blacher (Joshua)
6.47K
0.85%
+6.47K
--
Sep 09, 2025
Vennare (Raymond F)
8.81K
1.16%
+8.33K
+1753.89%
Sep 09, 2025
Nuzum (Charles Lee Sr)
6.31K
0.83%
+4.31K
+216.25%
Sep 09, 2025
St Clair (Gregory Sr)
5.72K
0.75%
+4.31K
+305.17%
Sep 09, 2025
Chung-Welch (Nancy)
5.60K
0.73%
+4.31K
+334.78%
Sep 09, 2025
Handley (Daniel E)
5.45K
0.71%
+4.31K
+379.91%
Sep 09, 2025
Hawryluk (Matthew)
4.95K
0.65%
+4.31K
+681.20%
Sep 09, 2025
查看更多
持股ETF
更新时间: 12月6日 周六
更新时间: 12月6日 周六
机构名称
占比
iShares Core S&P Total U.S. Stock Market ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
占比0%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
Sep 25, 2025
Merger
15→1
Apr 20, 2023
Merger
20→1
Apr 20, 2023
Merger
20→1
Apr 20, 2023
Merger
20→1
Apr 20, 2023
Merger
20→1
公告日期
类型
比率
Sep 25, 2025
Merger
15→1
Apr 20, 2023
Merger
20→1
Apr 20, 2023
Merger
20→1
Apr 20, 2023
Merger
20→1
Apr 20, 2023
Merger
20→1
常见问题
Predictive Oncology Inc的前五大股东是谁？
Predictive Oncology Inc 的前五大股东如下：
Blacher (Joshua)持有股份：6.47K，占总股份比例：0.85%。
Vennare (Raymond F)持有股份：8.81K，占总股份比例：1.16%。
Nuzum (Charles Lee Sr)持有股份：6.31K，占总股份比例：0.83%。
St Clair (Gregory Sr)持有股份：5.72K，占总股份比例：0.75%。
Chung-Welch (Nancy)持有股份：5.60K，占总股份比例：0.73%。
Blacher (Joshua)持有股份：6.47K，占总股份比例：0.85%。
Vennare (Raymond F)持有股份：8.81K，占总股份比例：1.16%。
Nuzum (Charles Lee Sr)持有股份：6.31K，占总股份比例：0.83%。
St Clair (Gregory Sr)持有股份：5.72K，占总股份比例：0.75%。
Chung-Welch (Nancy)持有股份：5.60K，占总股份比例：0.73%。
Predictive Oncology Inc的前三大股东类型是什么？
Predictive Oncology Inc 的前三大股东类型分别是：
Luo (Weiyu)
SLN Capital Ltd
Diametric Capital
Luo (Weiyu)
SLN Capital Ltd
Diametric Capital
有多少机构持有Predictive Oncology Inc(POAI)的股份？
截至2025Q3，共有37家机构持有Predictive Oncology Inc的股份，合计持有的股份价值约为7.39K，占公司总股份的0.21%。与2025Q2相比，机构持股有所增加，增幅为-2.72%。
哪个业务部门对Predictive Oncology Inc的收入贡献最大？
在--，--业务部门对Predictive Oncology Inc的收入贡献最大，创收--，占总收入的--%。
